Low-grade glioma pediatric · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Dabrafenib and Trametinib Variant #01 | — | R 52 791 | 28d | ~10.7 mo | — | ~12 | ~R 633 492 PFS proxy · indirect | 6 |
Temozolomide monotherapy Variant #13 | — | R 8 153 | 28d | ~4.0 mo | ~16.3 mo | ~5 | ~R 40 764 PFS proxy · indirect | 10 |
Cisplatin and Etoposide (EP) Variant #01 | — | R 4 264 | 42d | ~5.0 mo | ~10.2 mo | ~4 | ~R 17 056 PFS proxy · indirect | 13 |
Carboplatin and Vincristine Variant #02 | — | R 4 168 | 28d | — | — | — | — | — |
Tovorafenib monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
5 of 5 regimens shown